A randomized prospective trial of ioxaglate 320 (Hexabrix) vs. iodixanol 320 (Visipaque) in patients undergoing percutaneous coronary intervention.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples